Eclinical Solutions
Eclinical Solutions is recorded as a service provider in 45 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 45 trials · Latest update first
A Phase 2 Open-Label, Multicenter Clinical Study of The Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/3 Study to Evaluate the Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment-Naïve Patients With Myelofibrosis
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients with Triple-class Refractory Multiple Myeloma
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Sponsor Relay Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants with Thyroid Eye Disease.
Sponsor Tourmaline Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Sponsor Geron Corp.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
Sponsor Morphic Therapeutic Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis
Sponsor Trace Neuroscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Sponsor Verastem Inc.
- Start (EU)
- Latest update
- Estimated end
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An International, Phase 3, Open-label, Randomized Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET)
Sponsor Morphic Therapeutic Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Eclinical Solutions?
The 2026-10-09 snapshot links Eclinical Solutions to 45 distinct CTIS trials. Recorded services include Data management, Electronic data capture, Statistical analysis, data organization/CTMS, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Eclinical Solutions?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Gastroenterology, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Eclinical Solutions conducted?
The linked trials record locations in 25 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Eclinical Solutions delivered services.
What can this page tell me about Eclinical Solutions's trial experience?
Browse 45 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Eclinical Solutions. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Eclinical Solutions LLC